Immunoselection Tumors

Tumor immunoselection therapy is a cancer treatment that uses the patient's immune system to fight the tumor. This method is based on the fact that the human immune system can recognize and attack cancer cells.

Immunoselection therapy can be carried out in various ways. One of them is the use of antibodies that bind to cancer cells and cause their destruction. Antibodies can be obtained from the patient's blood or synthesized in a laboratory.

Another method of immunoselection therapy is the use of interferons. Interferons are proteins that are produced by the immune system in response to infection. They can kill cancer cells and prevent them from multiplying.

The third method is the use of immunomodulators, which stimulate the immune system and help it fight cancer.

The advantages of immunoselection therapy for tumors include its high efficiency, safety for healthy tissues, and the possibility of use in patients with weakened immune systems. However, this treatment is still in the research stage and its effectiveness and safety have not been proven in clinical studies.

Tumor immunoselection is an effective way to combat malignant tumors by increasing the activity of the immune system. These tumors are very resistant to chemotherapy, radiotherapy, and targeted therapy. They are also distinguished by their high growth rate. Intensive spread of the disease throughout the body and subsequent relapse complicate the treatment process.

Research into the mechanisms of this method has led to the fact that during immunoselection, the immune system uses a specific counteraction. Thanks to which it is possible to concentrate therapeutic efforts on the affected area of ​​the patient’s body.

How is immunoselection therapy for malignant neoplasms carried out? The idea of ​​treatment is based on the use of vaccines. The vaccine triggers immune cells involved in destroying pathogens. During an immune reaction to the formation of an abnormal protein, the tumor loses its ability to reproduce and, as a result, its growth is inhibited. Thus, the connection between the tumor cells and the intercellular fluid is broken. As a result of destruction, the body is completely or partially cleansed of malignant cells. Currently, the drug Darnellumab, which is a monoclonal antibody aimed at activating the innate immune system, is registered in Russia. It is used in oncology, hematology for Burkitt's lymphoma in combination with chemotherapy. This type of cancer is quite rare and is most often reported in children. The use of the drug is also indicated for pulmonary, inguinal, occipital lymphoma and other neoplasms localized in the nasopharynx and lungs. According to studies, this may increase patient survival. Thus, immunoselection treatment is an innovative method. But so far it is not widespread and is only successfully used